Regulation of GABA(A) receptor subunit expression by pharmacological agents

Pharmacological Reviews
Mikko Uusi-Oukari, E R Korpi

Abstract

The gamma-aminobutyric acid (GABA) type A receptor system, the main fast-acting inhibitory neurotransmitter system in the brain, is the pharmacological target for many drugs used clinically to treat, for example, anxiety disorders and epilepsy, and to induce and maintain sedation, sleep, and anesthesia. These drugs facilitate the function of pentameric GABA(A) receptors that exhibit widespread expression in all brain regions and large structural and pharmacological heterogeneity as a result of composition from a repertoire of 19 subunit variants. One of the main problems in clinical use of GABA(A) receptor agonists is the development of tolerance. Most drugs, in long-term use and during withdrawal, have been associated with important modulations of the receptor subunit expression in brain-region-specific manner, participating in the mechanisms of tolerance and dependence. In most cases, the molecular mechanisms of regulation of subunit expression are poorly known, partly as a result of neurobiological adaptation to altered neuronal function. More knowledge has been obtained on the mechanisms of GABA(A) receptor trafficking and cell surface expression and the processes that may contribute to tolerance, although their possible ph...Continue Reading

References

May 13, 1977·Brain Research·G A Banker, W M Cowan
Aug 1, 1992·Proceedings of the National Academy of Sciences of the United States of America·J M FritschyH Möhler
May 12, 1992·European Journal of Pharmacology·R J Primus, D W Gallager
Dec 8, 1992·The Journal of Comparative Neurology·E PersohnJ G Richards
Oct 1, 1992·Proceedings of the National Academy of Sciences of the United States of America·P BovolinD Grayson
Jun 1, 1991·British Journal of Pharmacology·I Kang, L G Miller
Jan 1, 1991·Journal of Substance Abuse Treatment·H Ashton
Jan 1, 1991·Annals of the New York Academy of Sciences·A L MorrowS M Paul
Sep 1, 1991·Drugs·M C Smith, B J Riskin
Jan 1, 1990·Journal of Molecular Neuroscience : MN·C HeningerD W Gallager
Nov 1, 1988·Pharmacology, Biochemistry, and Behavior·E P BonettiP Polc
Jan 1, 1985·Neuroscience and Biobehavioral Reviews·S E File
Jan 17, 1989·European Journal of Pharmacology·R J Marley, D W Gallager
Jun 1, 1985·British Medical Journal·L DennersteinG D Burrows
Jan 1, 1981·The Journal of Comparative Neurology·S Rothman, W M Cowan
Mar 1, 1995·Neuropharmacology·H LüddensP H Seeburg
Nov 1, 1994·Addiction·H Pétursson
May 1, 1994·Brain Research. Molecular Brain Research·M Mhatre, M K Ticku
Jan 1, 1994·Neurochemical Research·T MiyaokaI K Ho

❮ Previous
Next ❯

Citations

Aug 28, 2012·European Archives of Psychiatry and Clinical Neuroscience·Caroline NothdurfterRainer Rupprecht
Sep 29, 2011·Pflügers Archiv : European journal of physiology·Jeffrey M Ellenbogen, Edward F Pace-Schott
Aug 17, 2012·ACS Chemical Neuroscience·Justin T Gass, M Foster Olive
Feb 13, 2013·ACS Chemical Neuroscience·J Robert LaneMeritxell Canals
Oct 24, 2012·Proceedings of the National Academy of Sciences of the United States of America·Tija C JacobStephen J Moss
Nov 8, 2013·Behavioural Pharmacology·Jonathan Cueto-EscobedoJuan F Rodríguez-Landa
Apr 27, 2012·Advances in Pharmacological Sciences·Christiaan H Vinkers, Berend Olivier
Sep 12, 2013·Molecular Neurobiology·Juu-Chin LuChih-Tien Wang
Oct 1, 2013·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Elena VashchinkinaEsa R Korpi
Feb 21, 2014·ACS Chemical Neuroscience·Nicholas E Calcaterra, James C Barrow
Dec 4, 2014·Molecular and Cellular Neurosciences·Géraldine GouzerAntoine Triller
Mar 26, 2013·Expert Opinion on Therapeutic Patents·Gabriella Guerrini, Giovanna Ciciani
Feb 13, 2016·Neurochemical Research·Xiaona WangPeng Sun
Dec 8, 2015·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Chen Li, Lynn G Kirby
May 22, 2013·The Psychiatric Clinics of North America·J Dave Barry, Brandon K Wills
Nov 15, 2012·Brain Research Bulletin·Jovana DivljakovićMiroslav M Savić
Sep 11, 2012·Progress in Neuro-psychopharmacology & Biological Psychiatry·Thomas LemppEllen Niederberger
Aug 2, 2011·Neurologic Clinics·J Dave Barry, Brandon K Wills
Aug 2, 2011·Progress in Neurobiology·Massimo Avoli, Marco de Curtis
Dec 1, 2015·Neurodegenerative Disease Management·Rosemary ClarkTracey Dickson
May 26, 2011·Journal of Neuroendocrinology·C NothdurfterR Rupprecht
Nov 7, 2012·Alcoholism, Clinical and Experimental Research·Daniela Rüedi-BettschenDonna M Platt
Mar 28, 2013·Brain and Behavior·C Jean LoriaRuth E Siegel
Nov 7, 2012·British Journal of Clinical Pharmacology·Sean David HoodGary Kenneth Hulse
Feb 14, 2015·Acta Physiologica·A BarraganB Birnir
Aug 5, 2015·Translational Psychiatry·T M MuellerJ H Meador-Woodruff
Mar 11, 2015·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Dongliang MaEyleen L K Goh
Apr 24, 2015·Journal of Neuroimmunology·Robert D SandersTracy Hussell
Apr 15, 2015·Homeopathy : the Journal of the Faculty of Homeopathy·Paolo BellaviteDebora Olioso

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.